CEPI, the Coalition for Epidemic Preparedness Innovations, announced the initiation of three programmes to develop vaccines against the novel coronavirus, nCoV-2019.
The programmes will leverage rapid response platforms already supported by CEPI as well as a new partnership. The aim is to advance nCoV-2019 vaccine candidates into clinical testing as quickly as possible.
The nCoV-2019 vaccine development efforts will build on existing partnerships with Inovio (Nasdaq: INO) and The University of Queensland (located in Brisbane, Australia). In addition, CEPI today announces a new partnership with Moderna, Inc., (Nasdaq: MRNA) and the U.S. National Institute of Allergy and Infectious Diseases.
Given the rapid global spread of the nCoV-2019 virus the world needs to act quickly and in unity to tackle this disease. Our intention with this work is to leverage our work on the MERS coronavirus and rapid response platforms to speed up vaccine development. There are no guarantees of success, but we hope this work could provide a significant and important step forward in developing a vaccine for this disease. Our aspiration with these technologies is to bring a new pathogen from gene sequence to clinical testing in 16 weeks – which is significantly shorter than where we are now, – Richard Hatchett, CEO of CEPI.